Esperion Therapeutics Inc. (NASDAQ:ESPR) saw unusually-strong trading volume on Tuesday . Approximately 820,535 shares changed hands during mid-day trading, an increase of 169% from the previous session’s volume of 304,522 shares.The stock last traded at $13.49 and had previously closed at $11.44.

Several equities analysts have recently commented on the stock. JMP Securities reaffirmed a “buy” rating and set a $67.00 price target on shares of Esperion Therapeutics in a research report on Thursday, June 16th. Credit Suisse Group AG cut shares of Esperion Therapeutics from a “neutral” rating to an “underperform” rating and reduced their price target for the stock from $23.00 to $10.00 in a research report on Wednesday, June 29th. JPMorgan Chase & Co. cut shares of Esperion Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price target for the stock from $50.00 to $15.00 in a research report on Wednesday, June 29th. Royal Bank Of Canada cut shares of Esperion Therapeutics from an “outperform” rating to a “sector perform” rating and reduced their price target for the stock from $30.00 to $15.00 in a research report on Wednesday, June 29th. Finally, Lake Street Capital reduced their price target on shares of Esperion Therapeutics from $80.00 to $27.00 and set a “buy” rating on the stock in a research report on Wednesday, June 29th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and six have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $24.40.

The company’s 50 day moving average is $10.98 and its 200 day moving average is $14.25. The stock’s market cap is $304.65 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/esperion-therapeutics-inc-espr-sees-unusually-high-trading-volume.html

Esperion Therapeutics (NASDAQ:ESPR) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.78) by $0.16. During the same quarter in the prior year, the company posted ($0.55) earnings per share. Equities research analysts forecast that Esperion Therapeutics Inc. will post ($3.37) EPS for the current fiscal year.

In other news, Director Mark E. Mcgovern bought 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 6th. The shares were purchased at an average price of $10.00 per share, for a total transaction of $50,000.00. Following the acquisition, the director now directly owns 600 shares of the company’s stock, valued at approximately $6,000. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. 35.40% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in ESPR. Rhenman & Partners Asset Management AB increased its position in shares of Esperion Therapeutics by 50.0% in the first quarter. Rhenman & Partners Asset Management AB now owns 150,000 shares of the biopharmaceutical company’s stock valued at $2,537,000 after buying an additional 50,000 shares during the period. BlackRock Institutional Trust Company N.A. increased its position in shares of Esperion Therapeutics by 1.4% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 330,950 shares of the biopharmaceutical company’s stock valued at $5,596,000 after buying an additional 4,471 shares during the period. Geode Capital Management LLC increased its position in shares of Esperion Therapeutics by 17.8% in the first quarter. Geode Capital Management LLC now owns 107,392 shares of the biopharmaceutical company’s stock valued at $1,815,000 after buying an additional 16,208 shares during the period. Jacobs Levy Equity Management Inc. purchased a new position in shares of Esperion Therapeutics during the first quarter valued at approximately $313,000. Finally, A.R.T. Advisors LLC increased its position in shares of Esperion Therapeutics by 93.6% in the first quarter. A.R.T. Advisors LLC now owns 200,858 shares of the biopharmaceutical company’s stock valued at $3,396,000 after buying an additional 97,112 shares during the period. Hedge funds and other institutional investors own 65.22% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

5 Day Chart for NASDAQ:ESPR

Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.